PIM1 and hepatoblastoma: To further support the role of PIM inhibition with AZD1208 in reducing the SCLCC phenotype and sensitizing hepatoblastoma cells to cisplatin, we sought to assess the role of the overexpression of PIM3 kinase on cancer cell stemness and sensitivity to cisplatin.